Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer.

EJNMMI research·2026
Same author

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Prostate cancer and prostatic diseases·2026
Same author

Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study.

Cancer science·2026
Same author

Circulating Tumor DNA Genomic Profiling in <sup>223</sup>Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Therapeutic effects of imidazoline 2 receptor activation on lower urinary tract dysfunction in a mouse model of spinal cord injury.

American journal of physiology. Renal physiology·2026

Related Experiment Video

Updated: Jun 8, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Kidney Cancer Working Group report.

Seiji Naito1, Yoshihiko Tomita, Sun Young Rha

  • 1Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. naito@uro.med.kyushu-u.ac.jp

Japanese Journal of Clinical Oncology
|September 28, 2010
PubMed
Summary

Kidney cancer incidence is rising globally, with significant differences in treatment response between Asian and Western populations. Further research is needed to optimize therapies for Asian patients, considering potential variations in drug efficacy and adverse events.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
09:31

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Published on: March 30, 2015

Related Experiment Videos

Last Updated: Jun 8, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
09:31

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Published on: March 30, 2015

Area of Science:

  • Oncology
  • Cancer Research
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) is the most common kidney cancer, with increasing global incidence and mortality.
  • While less common in Asia, RCC rates are rising in developed Asian nations.
  • Known risk factors include smoking, obesity, and genetic susceptibility.

Purpose of the Study:

  • To review current kidney cancer treatment guidelines and their applicability to Asian populations.
  • To highlight the need for research into efficacy and toxicity of targeted therapies in Asian patients.
  • To address disparities in adverse event profiles observed between Asian and non-Asian individuals.

Main Methods:

  • Review of National Comprehensive Cancer Network guidelines for kidney cancer treatment.
  • Analysis of existing data on immunotherapy and molecular-targeted drugs for metastatic RCC.
  • Examination of population-based differences in drug adverse events.

Main Results:

  • Surgical excision is recommended for early-stage kidney cancer.
  • Immunotherapy (e.g., interleukin-2, interferon-alpha) and targeted therapies (e.g., sunitinib, sorafenib) are used for advanced disease.
  • Significant differences in adverse events from targeted drugs like sorafenib and sunitinib exist between Asian and non-Asian populations.

Conclusions:

  • Current treatment guidelines are largely based on Western clinical trials.
  • Dosage optimization for targeted therapies may be necessary for Asian patients due to potential differences in drug metabolism and toxicity.
  • Further research is crucial to develop tailored treatment strategies for kidney cancer in Asian populations.